Examining Clinical Guidelines for the Adoption of Genomic Testing: A Workshop

Committee

Mylynda Massart

Co-Chair

Mylynda B. Massart, M.D., Ph.D., is a board-certified Family Medicine physician at UPMC, and associate professor at the University of Pittsburgh. She currently serves as the founder and Medical Director of the UPMC Primary Care Precision Medicine clinic and as the Associate Director of Clinical Services for the Institute for Precision Medicine. Dr. Massart is co-director of the HUB Core over Research Inclusivity and Community Partners Core at the Clinical and Translational Science Institute (CSTI). She has an interest in emerging technologies in multi-cancer early detection and frequently speaks on these topics through the speaker bureau at GRAIL. Her research interests are in developing education in genetics and precision medicine for primary care providers and trainees and being a research catalyst facilitating the inclusion of underrepresented populations in biomedical research. She teaches residents and medical students in her clinic and at the hospital and serves as medical director for Bethany Hospice. Dr. Massart is MPI of the Community Engagement Alliance Consultative Resource (CEACR), a partnership between the University of Pittsburgh CTSI and Community-Campus Partnerships for Health.

Victoria M. Pratt

Co-Chair

Victoria (Vicky) Pratt, Ph.D., FACMG, is Director of Scientific Affairs for Pharmacogenetics at Agena Bioscience and the Past President of Association for Molecular Pathology (AMP). Dr. Pratt continues to serve on the Centers for Disease Control and Prevention (CDC) GeT-RM program for reference materials for Molecular Genetics, the National Academy of Medicine's Roundtable on Genomics and Precision Health, and the American Medical Association's (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory committee. She has developed guidelines with AMP related to genetic and pharmacogenetic testing including for CYP2C19, CYP2C9, Warfarin-related genes, CYP2D6, TPMT/NUDT15, CYP3A4/CYP3A5, and DPYD. Dr. Pratt graduated with a Ph.D. in Medical and Molecular Genetics from Indiana University School of Medicine. Her fellowship training was in Ph.D. Medical and Clinical Molecular Genetics at Henry Ford Hospital, Detroit MI.

Trish Brown

Member

Trish Brown, M.S., CGC, is the current the Executive Director of Genomics and Precision Medicine for CVS Health. In this role she provides evidence based clinical consultation and guidance on precision medicine for companies and business units within the CVS Health enterprise. She currently serves on the Board of Directors for Midwives on Missions of Service (MOMS), a not-for profit organization that teaches evidence-based maternity care to Community Health Care Workers in Sierra Leone. Trish serves on the National Society of Genetic Counselors (NSGC) expert media panel to provide education about Medicare, Medicaid and Commerical insurance coverage policies. Prior to joining CVS Health, she has held executive leadership roles at distinguished corporations such as Illumina, LabCorp and Medco, and the entrepreneurial successes DNA Direct, Fabric Genomics, and BeaconLBS. Through her work she seeks to bridge business strategy with clinical care expertise and drive positive outcomes for healthcare consumers and the businesses that serve them. Trish attended the University of California, Davis and earned a master's degree in human genetics from Sarah Lawrence College. She is certified by the American Board of Genetic Counseling.

Pranil Chandra

Member

Pranil Chandra, D.O., joined PathGroup in 2011 as Associate Medical Director of Molecular Pathology and now currently serves as Senior Vice President and Chief Genomics Officer at PathGroup. Dr. Chandra holds board certifications in anatomic and clinical pathology, hematopathology and molecular genetic pathology. He completed his AP/CP training and fellowships in hematopathology, oncologic pathology and molecular pathology at NYU Langone Medical Center and the University of Texas-MD Anderson Cancer Center, respectively. While at MD Anderson, he served as Chief Fellow and received numerous awards for his research in acute myeloid leukemia. He has presented numerous abstracts and platform presentations at various pathology meetings and has published peer-reviewed articles and book chapters. Dr. Chandra is a member of the American Society of Clinical Pathology, College of American Pathologists, and Association of Molecular Pathology where he also serves in a leadership capacity to the Economic Affairs Committee as Vice-Chair of Coverage. Dr. Chandra is a recognized medical consultant in molecular pathology and personalized medicine and is considered a national thought leader in Precision Medicine and Cancer Genomics.

W. Gregory Feero

Member

W. Gregory Feero, M.D., Ph.D., is a family medicine physician and human genetics specialist. Serving at Four Seasons Family Practice in Fairfield from 2001-06, Dr. Feero rejoined Maine General Medical Center's active staff at Four Seasons in July 2009 after working as chief of the Genomic Healthcare Branch of the National Human Genome Research Institute, National Institutes of Health in Bethesda, MD. Dr. Feero received a Doctorate in Human Genetics from the University of Pittsburgh Graduate School of Public Health and his medical degree from the University of Pittsburgh School of Medicine. He also serves as a faculty member in the Maine Dartmouth Family Medicine Residency program and is a Professor for the Department of Community and Family Medicine at the Geisel School of Medicine at Dartmouth in Hanover, NH. He is a co-chair for the Roundtable on Genomics and Precision Health of the National Academies of Sciences, Engineering and Medicine.

Gabriel Lazarin

Member

Gabriel Lazarin, M.S., CGC, is currently the Vice President, Medical Affairs for Myriad Women’s Health, part of Myriad Genetics. Myriad is a genetic testing and precision medicine company that develops and offers genetic tests that help assess the risk of developing certain diseases or disease progression. In this position, Gabriel connects with clinicians to primarily discuss technology and practice around reproductive and hereditary cancer genetics. He has worked or advised several genomics, biotech, or healthcare tech startups toward integrating innovative technologies and workstreams into mainstream clinical care. In particular, he has been active in the introduction of new technologies in reproductive genetic testing, including expanded carrier screening and prenatal cell-free DNA screening. He has published on utility, usage, and delivery of these tests, building evidence toward widespread adoption. Gabriel is genetic counselor, certified by the American Board of Genetic Counseling, and has 15 years of experience in the molecular diagnostics industry.

Funda Meric-Bernstam

Member

Funda Meric-Bernstam, M.D., is the Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, and Medical Director of the Institute of Personalized Cancer Therapy. In her capacities at MD Anderson, she has collaborated with many large pharmaceutical companies. She has extensive experience in novel therapeutics, with a focus on genomically-informed therapeutics and antibody-drug conjugates, as well as high throughput -omic technologies and correlative studies. She leads one of the premiere Phase I programs in the world, as well as several large-scale initiatives in precision oncology such as ComboMATCH. She has established a Precision Oncology Decision Support Team at MD Anderson that provides point of care input for actionability, builds a framework for rapid assessment of actionability of molecular alterations, launched a public website “www.personalizedcancer therapy.org” providing access to expert curation of information on therapeutic relevance of specific genes/variants created, created a knowledgebase and clinical trial alert systems that facilitate accrual to genotype-selected trials across the institution, and established efforts to monitor therapy after genomic testing to identify obstacles to trial enrollment. She also leads a basic and translational research program centered around cell signaling, biomarker discovery, and molecular therapeutics, with specific focus on antibody-drug conjugates, precision oncology, and patient-derived models.

Rebecca Morgan

Member

Rebecca L. Morgan, Ph.D., M.P.H., a health research methodologist and epidemiologist, is a part-time Assistant Professor at McMaster University, Department of Health Research Methods, Evidence and Impact, in Hamilton, Ontario and adjunct Assistant Professor at Case Western Reserve University, School of Medicine, in Cleveland, OH, and Executive Director of Evidence Foundation. Much of Dr. Morgan’s research on evidence synthesis and guideline development has focused on advancing methods for assessing environmental and occupational exposures, integration of non-randomized studies, guideline collaboration, and rapid or living reviews. Dr. Morgan serves as the Chair of the Guidelines Collaboration Working Group within the Guideline International Network, and Chair of the Environmental and Occupational Health Project Group within the GRADE Working Group. She joined the GRADE Working Group in 2009 and has extensive experience in teaching systematic review and guideline development methods to national and international audiences. Dr. Morgan serves as a methodologist for global organizations such as the Advisory Committee on Immunization Practices, Infectious Diseases Society of America, Health Canada, the World Health Organization, among others. Dr. Morgan is a founding member of the U.S. GRADE Network and Evidence Foundation, a registered nonprofit whose mission is to support evidence-based health care through training, mentorship, education, and collaboration.

Wanda K. Nicholson

Member

Wanda Nicholson, M.D., M.P.H., M.B.A., is dually trained in obstetrics and gynecology and epidemiology and is committed to evidence-based medicine and preventive care to improve patient outcomes. She is Chair of the United States Preventive Services Task Force and professor of prevention and community health at the Milken Institute School of Public Health at the George Washington University (GWU) in Washington, D.C and holds a joint appointment in the Department of Obstetrics and Gynecology at the GWU School of Medicine. She is the Director of the School of Public Health Patient-centered Outcomes in Women's Endocrine and Reproductive Health (POWER). Prior to joining GW, she was a co-I for "Comparing Options for Management: Patient-centered Results for Uterine Fibroids (COMPARE-UF), a 5-year PCORI-funded study. She is an MPI on an NICHD-funded study to conduct longitudinal follow-up of participants in the COMPARE study. She is immediate past vice president of the board of directors of the American Board of Obstetrics & Gynecology; past chair of the American College of Obstetricians and Gynecologists (ACOG) Diversity, Equity, and Inclusive Excellence Workgroup; and a past member of the executive board of ACOG and former chair of the Committee on Pregnancy and Postpartum Hemorrhage for the International Federation of Obstetrics and Gynecology (FIGO).

Mary Nix

Member

Mary Nix, M.S., PMP, is the Deputy Director of the Division of Practice Improvement at AHRQ. She is a health services research division leader, public servant, and certified project manager. Her master's degree is in clinical pathology, and she led laboratory testing operations in large academic medical centers assuring test accuracy and validity in support of high-quality patient care. In health services research, Mary has focused on data that informs clinical decisions and spent over 20 years on AHRQ's National Guideline Clearinghouse (NGC), reviewing thousands of clinical practice guidelines for scientific merit and trustworthiness. More recent work with researchers in the field moving evidence into practice reveals opportunities to improve guidelines' intrinsic and extrinsic factors toward swift and effective implementation.

Pim Suwannarat

Member

Pim Suwannarat, M.D., is a clinical geneticist and biochemical geneticist. She is the Regional Medical Director of Genetics and Genomics at the Mid-Atlantic Permanente Medical Group. She leads a team of genetic counselors and geneticists in providing prenatal, cancer, and clinical genetic care across the lifespan to the Kaiser Permanente Mid-Atlantic States members. This includes implementation of various strategies to improve access to evidence based genetic testing and counseling. At the KP National level she chairs the Clinical Practice Workgroup that helps inform the Precision Medicine, Genetics and Genomics direction for the organization resulting in implementation of patient and provider education, care management guidelines, and processes to identify individuals at risk for genetic conditions including CDC3 tier 1 conditions. Dr. Suwannarat completed her medical education from Chiangmai University, Chiangmai, Thailand. She did her pediatric residency training at Inova Fairfax Hospital for Children and her clinical and clinical biochemical genetics training with the National Human Genome Research Institute, NIH.